Bimekizumab 160mg/1ml solution for injection pre-filled disposable devices
NHS hospitals in England used £52,065,216 of indicative cost of Bimekizumab 160mg/1ml solution for injection pre-filled disposable devices in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 28.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Bimekizumab 160mg/1ml solution for injection pre-filled disposable devices: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Bimekizumab 160mg/1ml solution for injection pre-filled disposable devices most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £2,985,346 |
| University Hpls Coventry & Warwick Trust | £1,622,152 |
| Western Sussex Hospitals Nhs Found Trust | £1,580,621 |
| Leeds Teaching Hpls Nhs Trust | £1,565,963 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,561,077 |
| Portsmouth Hospitals Nhs Trust | £1,380,295 |
| Royal Free London Nhs Foundation Trust | £1,245,930 |
| Co.durham & Darlington Nhs Foundation Tr | £1,201,956 |
| Southend Univ Hosp Nhs Foundation Trust | £1,134,774 |
| Bradford Teaching Hospitals Nhs Ft | £1,131,109 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.